GlassScriptPhysician profile
Mohamad H Taha
NPI 1629488473
$10,350.39
in general payments reported to CMS, 2019-2025
23 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $7,569 · 2021: $70.39 · 2022: $704 · 2023: $741 · 2024: $546 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $7,552.22 | 2020 | |
| Abbott Laboratories | $605.60 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ultreon, Cardiomems |
| Abiomed | $496.89 | 2022-2024 | Impella |
| Medtronic, INC. | $338.71 | 2022-2025 | Symplicity G3, Abre |
| Novartis Pharmaceuticals Corporation | $214.76 | 2019-2024 | |
| Astellas Pharma US INC | $166.91 | 2019 | |
| Amgen INC. | $120.03 | 2023-2024 | Repatha |
| Biotronik INC. | $117.34 | 2022 | |
| Philips North America LLC | $103.51 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.54 | 2023-2025 | Lifevest |
| Inari Medical, INC. | $73.32 | 2022 | |
| Boston Scientific Corporation | $70.39 | 2021 | |
| Lantheus Medical Imaging, INC. | $65.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.61 | 2022-2023 | |
| Shockwave Medical, INC | $54.29 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.72 | 2022-2023 | Xarelto |
| Bridgebio Pharma, INC. | $51.30 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $26.40 | 2023 | Optimizer |
| Pfizer INC. | $23.66 | 2024 | |
| Kestra Medical Technology Services, INC. | $22.27 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $20.31 | 2023 | Verquvo |
| Baxter Healthcare | $17.56 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $16.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.